Slide 1: First Quarter 2024 Operating & Financial Results Conference Call
First Quarter 2024 Operating & Financial Results Conference Call / Webinar May 9th, 2024 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave 01 Introduction CEO and President CFO 02 2024 Q1 Highlights 03 Financial Highlights 04 Starlight Therapeutics 05 ADC Program 06 Other Operational Highlights 07 Q&A
Slide 4: 1st Quarter Highlights 1 of 2
2024 ü Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 expected and on-track for the second half of 2024 . 1st Quarter ü Obtained regulatory allowance to begin Phase 2 Harmonic™ Highlights clinical trial enrollment in Japan and Taiwan
Slide 5: 1st Quarter Highlights 2 of 2
2024 ü Starlight Therapeutics , a wholly owned subsidiary of Lantern Pharma focused on CNS and brain cancers with STAR-001, advanced with the filing of a clinical trial protocol for the 1st Quarter Phase 1b dose optimization and expansion cohort in recurrent IDH wild-type high grade gliomas. Highlig
Slide 6: Lantern's diverse & unique AI-driven pipeline of drug programs
Lantern’s diverse & unique AI-driven pipeline of 11 drug programs including RADR® collaborations and Starlight Therapeutics Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation Disease Non-Small Cell Lung Cancer LP-300 for N
Slide 7: Starlight's pipeline is focused on multiple CNS indications
Starlight’s pipeline is focused on multiple CNS indications in both adult and pediatric patients Starlight Therapeutics ADULT CNS CANCERS Orphan Rare Pediatric Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation Disease Glioblastoma (GBM)* STAR-001 Brain Metastases (TNBC)**
Slide 8: Financial updates Q1 2024
Financial updates Q1 2024 Solid financial position & capital efficiency fuel continued growth & give Lantern cash runway into at least Q3 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended March 31, (unaudited) 03/31/2024 12/31/2023 2024 2023 (unaudited) Operati
Slide 9: Advancing Starlight Therapeutics with hiring of Chief Medical Officer
Advancing Starlight Therapeutics with hiring of Chief Medical Officer (CMO) Marc Chamberlain, MD Dr. Chamberlain, Marc Marc Chamberlain, M.D. CMO of Starlight Leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research wit
Slide 10: Starlight has blockbuster potential to provide new treatment options for 500,000+ patients
Born from billions of datapoints & AI, Starlight has blockbuster potential to provide new treatment options for 500,000+ patients There are over 120 types of central nervous system (CNS) and brain 5 Year Survival cancers and a majority have no Rates of CNS And Brain Cancers effective treatment optio
Slide 11: STAR-001 has potent anti-tumor efficacy in GBM mouse models
STAR-001 has potent anti-tumor efficacy in methylated and unmethylated GBM mouse models STAR-001 demonstrates 3,000X higher in vitro potency compared to temozolomide - independent of MGMT status STAR-001 potency in MGMT Negative MGMT Positive MGMT negative and * * * *Cell lines MGMT positive (temozo
Slide 12: Unique position of STAR-001 compared to current therapeutic options
Unique position of STAR-001 compared to current therapeutic options CURRENTLY APPROVED MAINSTAY GBM THERAPIES STAR-001 Temozolomide (TMZ) Nitrosourea (CCNU) Molecular weight 304 kD 194 kD 233 kD Derivation Mushroom Synthetic Synthetic Omphalotus illudens* Nitrogen Mustards Cyclohexylamine + Chemistr
Slide 13: Current RADR modules - focused on key oncology issues
Current RADR® modules - focused on key oncology issues 1 MoA Discovery - Integration of knowledge from biological networks and machine learning to better understand the drugs’ Mechanism of Action 1 MoA Discovery 2 Drug Response Prediction - Machine learning pipelines to Biomarker predict drug respon
Slide 14: Novel, highly potent, cryptophycin-based ADC preclinical proof-of-concept
Advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC (Cp-ADC) ADC Collaboration Update Key Highlights • The cryptophycin(Cp) drug-payload and Cp-ADC High HER2 Expression Moderate HER2 Expression averaged an 80% cancer cell kill rate
Slide 15: AI-powered module to deliver differentiated and derisked ADCs faster
Al-powered module has potential to deliver differentiated and derisked ADCs faster & with significantly reduced costs Leveraging AI to deliver Antibody novel, differentiated ADCs Ability to select and characterize among potent and super potent payloads with specific and optimized molecular and bioch
Slide 16: Lantern Pharma 2024 webinar series – Webinar Wednesdays
Lantern pharma 2024 webinar series – Webinar Wednesdays – featuring world-class collaborators and researchers Future Webinar Wednesdays MAY 29th LP-184 in Pancreatic Cancer and Other Solid Tumors with Dr. Igor Astsaturov of Fox Chase Cancer Center MAY 31st Bladder Cancer Awareness Month – Precision
Slide 17: Publications highlighting the clinical value of RADR insights
Publications highlighting the clinical value of RADR® insights & de-risking the development of Lantern’s drug candidates POSTER | AACR ANNUAL MEETING 2024 Phase 1a/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphoma
Slide 18: 2024 Objectives
2024 Objectives A Breakthrough Year for Lantern ● Complete Phase 1a clinical trial for LP-184; commence Phase 1b and investigator led trial(s) T ● Accelerate enrollment in first-in-human clinical trial for LP-284 in NHL + other cancers O ● Commence enrollment of The Harmonic™ Trial in targeted sites
Slide 19: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com CONNECT WITH US @LanternPharma linkedin.com/company/lanternpharma